Sanofi’s Wayrilz wins approval in the EU

The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. This follows the positive opinion by the European Medicines Agency's human medicines advisory committee, the CHMP.

According to its developer, French pharma major Sanofi (Euronext: SAN), Wayrilz can help address the underlying causes of ITP through multi-immune modulation, targeting different pathways across the immune system.